Akeso Sustainability Profile
Akeso, Inc., a leading biopharmaceutical company headquartered in China (CN), is renowned for its innovative approach in the fields of oncology and autoimmune diseases. Founded in 2007, Akeso has rapidly established itself as a key player in the biopharma industry, with a strong focus on the research, development, and commercialisation of monoclonal antibodies and bispecific antibodies. With major operational regions across Asia and expanding into global markets, Akeso's core products include its proprietary therapies that target various cancers and immune disorders. The company is distinguished by its commitment to advancing biologics, leveraging cutting-edge technology to enhance treatment efficacy. Notably, Akeso has achieved significant milestones, including successful clinical trials and partnerships that bolster its market position, making it a formidable contender in the competitive biopharmaceutical landscape.
DitchCarbon Score
How does Akeso's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Akeso's score of 26 is lower than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Akeso's reported carbon emissions
In 2024, Akeso reported total carbon emissions of approximately 64,084,460 kg CO2e for Scope 1 and 46,019,810 kg CO2e for Scope 2, resulting in a combined total of about 52,428,270 kg CO2e. This marks a significant increase from 2023, where emissions were approximately 1,397,580 kg CO2e for Scope 1 and 26,831,850 kg CO2e for Scope 2, totalling around 28,229,430 kg CO2e. In 2022, Akeso's emissions were approximately 82,000 kg CO2e for Scope 1 and 23,658,020 kg CO2e for Scope 2, leading to a total of about 23,740,020 kg CO2e. The company has shown a progressive increase in emissions over the years, with 2021 reporting approximately 35,230 kg CO2e for Scope 1 and 4,495,650 kg CO2e for Scope 2, totalling around 4,530,880 kg CO2e. In 2020, emissions were approximately 44,390 kg CO2e for Scope 1 and 4,129,630 kg CO2e for Scope 2, resulting in a total of about 4,174,020 kg CO2e. Despite the increase in emissions, Akeso has not set specific reduction targets or initiatives as part of their climate commitments. The company does not disclose any Scope 3 emissions data, which may indicate a focus on direct and indirect emissions from their operations. All emissions data is sourced directly from Akeso, Inc., with no cascaded data from a parent or related organization.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 44,390 | 00,000 | 00,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 4,129,630 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - |
How Carbon Intensive is Akeso's Industry?
How Carbon Intensive is Akeso's Location?
Akeso's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Akeso has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
